Abstract
The effects of imatinib are partly mediated by the inhibition of platelet-derived growth factor (PDGF), which is highly expressed in the liver. In this phase-I/II trial pharmacokinetic parameters of imatinib given for hepatocellular cancer were similar to those previously derived from CML patients. The AUC of N-desmethyl-imatinib depended on liver function; the metabolism of imatinib was otherwise comparable to other populations. During short-termed imatinib treatment (4 weeks, 400 mg/d), plasma PDGF significantly decreased. The AUC of N-desmethyl-imatinib could best be attributed to the pharmacodynamic effect of PDGF inhibition (r=-0.679 [95% CI: -0.917 to -0.0868], p=0.031).
Publication types
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
MeSH terms
-
Aged
-
Angiogenesis Inhibitors / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / blood
-
Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Becaplermin
-
Benzamides
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / metabolism
-
Carcinoma, Hepatocellular / pathology
-
Female
-
Humans
-
Imatinib Mesylate
-
Liver / drug effects
-
Liver / metabolism*
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / metabolism
-
Liver Neoplasms / pathology
-
Male
-
Middle Aged
-
Models, Biological
-
Octreotide / administration & dosage
-
Piperazines / administration & dosage
-
Piperazines / blood
-
Piperazines / pharmacokinetics*
-
Platelet-Derived Growth Factor / antagonists & inhibitors
-
Platelet-Derived Growth Factor / metabolism
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / blood
-
Protein Kinase Inhibitors / pharmacokinetics*
-
Proto-Oncogene Proteins c-sis
-
Pyrimidines / administration & dosage
-
Pyrimidines / blood
-
Pyrimidines / pharmacokinetics*
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Vascular Endothelial Growth Factor A / blood
Substances
-
Angiogenesis Inhibitors
-
Benzamides
-
Piperazines
-
Platelet-Derived Growth Factor
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins c-sis
-
Pyrimidines
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Becaplermin
-
Imatinib Mesylate
-
Octreotide